首页> 美国卫生研究院文献>The Journal of Biological Chemistry >The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote Tumor Metastasis
【2h】

The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote Tumor Metastasis

机译:Prometastatic核糖体S6激酶2-cAMP反应元件结合蛋白(RSK2-CREB)信号通路上调肌动蛋白结合蛋白Fascin-1促进肿瘤转移。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Metastasis is the leading cause of death in patients with breast, lung, and head and neck cancers. However, the molecular mechanisms underlying metastases in these cancers remain unclear. We found that the p90 ribosomal S6 kinase 2 (RSK2)-cAMP response element-binding protein (CREB) pathway is commonly activated in diverse metastatic human cancer cells, leading to up-regulation of a CREB transcription target Fascin-1. We also observed that the protein expression patterns of RSK2 and Fascin-1 correlate in primary human tumor tissue samples from head and neck squamous cell carcinoma patients. Moreover, knockdown of RSK2 disrupts filopodia formation and bundling in highly invasive cancer cells, leading to attenuated cancer cell invasion in vitro and tumor metastasis in vivo, whereas expression of Fascin-1 significantly rescues these phenotypes. Furthermore, targeting RSK2 with the small molecule RSK inhibitor FMK-MEA effectively attenuated the invasive and metastatic potential of cancer cells in vitro and in vivo, respectively. Taken together, our findings for the first time link RSK2-CREB signaling to filopodia formation and bundling through the up-regulation of Fascin-1, providing a proinvasive and prometastatic advantage to human cancers. Therefore, protein effectors of the RSK2-CREB-Fascin-1 pathway represent promising biomarkers and therapeutic targets in the clinical prognosis and treatment of metastatic human cancers.
机译:转移是乳腺癌,肺癌和头颈癌患者的主要死亡原因。然而,这些癌症中潜在的转移分子机制尚不清楚。我们发现,p90核糖体S6激酶2(RSK2)-cAMP反应元件结合蛋白(CREB)途径通常在多种转移性人类癌细胞中被激活,从而导致CREB转录靶Fascin-1的上调。我们还观察到,在头颈部鳞状细胞癌患者的原发性人类肿瘤组织样本中,RSK2和Fascin-1的蛋白质表达模式相关。此外,敲除RSK2会破坏高侵袭性癌细胞中的丝状伪足形成和束缚,从而导致体外癌细胞侵袭和体内肿瘤转移的减弱,而Fascin-1的表达则显着拯救了这些表型。此外,用小分子RSK抑制剂FMK-MEA靶向RSK2分别有效地减弱了癌细胞在体外和体内的侵袭和转移潜能。综上所述,我们的发现首次通过Fascin-1的上调将RSK2-CREB信号传导与丝状伪足形成和捆绑联系在一起,为人类癌症提供了侵袭性和转移性优势。因此,RSK2-CREB-Fascin-1途径的蛋白质效应子在转移性人类癌症的临床预后和治疗中代表着有希望的生物标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号